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Detection of estrogens in the environment has 
raised concerns in recent years because of the 
potential of these compounds to affect both 
wildlife and humans. The incomplete removal 
by publicly owned treatment works (POTWs) 
of excreted endogenous estrogens and pre­
scribed estrogens leads to their introduction 
into surface waters and potentially into drink­
ing water sources that rely on surface water. 
Estrogens, specifically estrone (E1), 17β­
estradiol (E2), estriol (E3), and ethinyl estradiol 
(EE2), have been detected in numerous studies 
of waste  water influents and effluents (Baronti 
et al. 2000; Belfroid et al. 1999; Desbrow et al. 
1998; Ferguson et al. 2001; Heberer 2002; 
Huang and Sedlak 2001; Huggett et al. 2003; 
Laganà et al. 2000; Mouatassim­Souali et al. 
2003; Nasu et al. 2001; Rodgers­Gray et al. 
2000; Spengler et al. 2001; Ternes et al. 1999a, 
1999b, 2002), and their presence has been con­
firmed in U.S. and European surface waters 
(Aherne and Briggs 1989; Belfroid et al. 1999; 
Heberer 2002; Kolodziej et al. 2003; Kolpin 
et al. 2002; Kuch and Ballschmiter 2001). 
More recently, several estrogens have also been 
detected in the source water of drinking water 
treatment plants but not in the finished water 
(Benotti et al. 2009).
The effects of estrogens on fish and other 
aquatic organisms have been widely studied 
(see Caldwell et al. 2008). However, fewer 
studies have evaluated the potential effects 
of estrogens in surface water on humans. 
Moreover, the available studies on exogenous 
estrogens reach differing conclusions on 
potential human effects (Aherne and Briggs 
1989; Andersson and Skakkebaek 1999; 
Christensen 1998; Webb et al. 2003). Based 
on independent worst­case exposure estimates, 
Aherne and Briggs (1989) and Christensen 
(1998) concluded that risks from environ­
mental sources of the synthetic hormone 
EE2 were negligible compared with normal 
body concentrations of estrogens. Webb et al. 
(2003) noted that worst­case indirect exposure 
to EE2 via drinking water would be three to 
four orders of magnitude lower than endog­
enous production rates of E2. Andersson and 
Skakkebaek (1999), however, raised concern 
that there may be no threshold level regarding 
the action of exogenous estrogens, particu­
larly for prepubertal males. Previous reports 
(Fritsche and Steinhart 1999; Hartmann et al. 
1998) concluded that dietary intake of the 
endogenous estrogens is minimal compared 
with human production rates.
For the most part, articles reporting detec­
tion of estrogens in surface and drinking waters 
both in the public press (Donn et al. 2008a, 
2008b, 2008c) and in the scientific literature 
(reviewed by Ying et al. 2002), provide little 
context as to whether potential drinking water 
exposures are large or small compared with 
other sources of exposure (e.g., dietary intake) 
or compared with acceptable daily intakes 
(ADIs). This makes it difficult to determine 
whether exposures from drinking water derived 
from surface water are a significant source of 
overall estrogen exposure or have the potential 
to exceed ADIs and, thus, whether they deserve 
additional evaluation.
The analysis presented here is, to our 
knowledge, the first exposure assessment for 
estrogens in drinking water that distinguishes 
among the potential sources of estrogens. In 
an earlier human health risk assessment of 
pharma  ceuticals in U.S. surface waters, Schwab 
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ba c K g r O u n D: Detection of estrogens in the environment has raised concerns in recent years 
because of their potential to affect both wildlife and humans. 
Objectives: We compared exposures to prescribed and naturally occurring estrogens in drinking 
water to exposures to naturally occurring background levels of estrogens in the diet of children and 
adults and to four independently derived acceptable daily intakes (ADIs) to determine whether 
drinking water intakes are larger or smaller than dietary intake or ADIs. 
Me t h O D s : We used the Pharmaceutical Assessment and Transport Evaluation (PhATE) model to 
predict concentrations of estrogens potentially present in drinking water. Predicted drinking water 
concentrations were combined with default water intake rates to estimate drinking water exposures. 
Predicted drinking water intakes were compared to dietary intakes and also to ADIs. We present 
comparisons for individual estrogens as well as combined estrogens.
re s u l t s: In the analysis we estimated that a child’s exposures to individual prescribed estrogens 
in drinking water are 730–480,000 times lower (depending upon estrogen type) than exposure to 
background levels of naturally occurring estrogens in milk. A child’s exposure to total estrogens in 
drinking water (prescribed and naturally occurring) is about 150 times lower than exposure from 
milk. Adult margins of exposure (MOEs) based on total dietary exposure are about 2 times smaller 
than those for children. Margins of safety (MOSs) for an adult’s exposure to total prescribed estro-
gens in drinking water vary from about 135 to > 17,000, depending on ADI. MOSs for exposure 
to total estrogens in drinking water are about 2 times lower than MOSs for prescribed estrogens. 
Depending on the ADI that is used, MOSs for young children range from 28 to 5,120 for total 
estrogens (including both prescribed and naturally occurring sources) in drinking water. 
cO n c l u s i O n s: The consistently large MOEs and MOSs strongly suggest that prescribed and total 
estrogens that may potentially be present in drinking water in the United States are not causing 
adverse effects in U.S. residents, including sensitive subpopulations.
Key w O r D s : acceptable daily intake, dietary intake, drinking water, environmental sources,   
estrogen, excretion, PhATE, phytoestrogen, surface water. Environ Health Perspect 118:338–344 
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et al. (2005) found no appreciable health risk 
from 26 drugs representing 14 different drug 
classes, but estrogens were not included in the 
study. In the present study we used a weight­
of­evidence approach to determine whether 
predicted exposure to trace levels of prescribed 
and naturally occurring estrogens in drinking 
water has the potential to cause effects. We 
developed several lines of evidence which fall 
into two general cate  gories.
The first category consists of comparing a 
typical U.S. resident’s potential drinking water 
exposures with background dietary exposures 
(e.g., exposure via consumption of milk or in 
the overall diet). Naturally occurring, animal­
derived estrogens (e.g., E1, E2, and E3) have 
been measured in a wide variety of foods that 
are regularly consumed by most Americans 
(Doyle 2000; Fritsche and Steinhart 1999; 
Hartmann et al. 1998; Henricks et al. 1983; 
Tsujioka et al. 1992). Dietary intake is likely 
the dominant pathway of estrogen exposure 
for most people in the United States of both 
sexes and all ages [except women using pre­
scribed estrogens for birth control, hormone 
therapy, or hormone replacement therapy) 
(Fritsche and Steinhart 1999)]. Although 
we do not know whether dietary exposures 
are or are not associated with effects (adverse 
or beneficial), we do know they represent a 
consistent daily exposure for U.S. residents. 
Whether drinking water exposures are large or 
small compared with dietary exposure to these 
same estrogens provides important perspective 
as to their relative significance.
The second category of lines of evidence 
consists of comparing drinking water exposures 
with toxicity­based benchmarks assumed to be 
without adverse effect [e.g., the World Health 
Organization (WHO) ADI, the threshold 
for toxicologic concern (TTC), occupational 
exposure limits, and Australian Guidelines for 
Water Recycling [Environment Protection and 
Heritage Council (EPHC) et al. 2008)]. These 
benchmarks represent estimates of exposure 
that are assumed to be safe and are derived 
using commonly accepted public health prac­
tices. Whether drinking water exposures are 
larger or smaller than these benchmarks indi­
cates whether they may or may not be associ­
ated with adverse effects.
Methods
Estimating exposure to estrogens via drinking 
water requires information about the concen­
trations of estrogens in drinking water and the 
amount of water consumed by a typical person 
in the United States. The U.S. Environmental 
Protection Agency (EPA) recommended water 
ingestion rates of 0.87 L/day for children and 
1.4 L/day for adults were used to estimate 
drinking water consumption (U.S. EPA 1997). 
Predicted concentrations in drinking water were 
used instead of meas  ured concentrations because 
few studies have measured estrogen concentra­
tions in U.S. drinking water, and those that are 
available report primarily non  detected concen­
trations [see Supplemental Material, available 
online (doi:10.1289/ehp.0900654.S1 via http://
dx.doi.org/); see also Hannah et al. 2009]. The 
predicted environ  mental concentrations (PECs) 
of synthetic estrogens and endogenous estrogens 
in drinking water resulting from human use 
and excretion were estimated using the PhATE 
(Pharmaceutical Assessment and Transport 
Evaluation) model, version 2.1.1 (Anderson 
et al. 2004). PhATE requires several compound­
specific inputs, including the per capita use or 
excretion rate, metabolism, POTW removal 
rate, in­stream removal, and drinking water 
treatment removal. Removal rates were not 
available for all estrogens. When no removal 
information was available for a particular estro­
gen and a particular removal mecha  nism, we 
assumed that no removal occurred to assure that 
drinking water PECs were not under  estimated. 
A summary of PhATE inputs is provided in the 
Supplemental Material, Tables SM­4 through 
SM­9 (doi:10.1289/ehp.0900654.S1). 
PhATE generates PECs for approximately 
2,710 stream segments in 11 U.S. watersheds 
and for 184 drinking water treatment plants 
serving approximately 10,800,000 people 
located on the modeled stream segments. The 
PECs used in this analysis are those for each of 
the drinking water treatment systems included 
in PhATE. PhATE is able to generate PECs for 
both mean flow conditions and 7Q10 low­flow 
(i.e., the lowest consecutive 7­day low flow that 
occurs on average once every 10 years) condi­
tions. To be conservative, in this analysis we 
used 7Q10 low­flow PECs because this is when 
estrogen concentrations in surface water used 
as source water for a drinking water treatment 
plant would be at their highest (as opposed 
to annual average flow when concentrations 
would be lower).
PECs generated by PhATE are grouped five 
ways to enable discrimination among differ­
ent sources of estrogens in drinking water and 
among types of estrogens. Potential exposures 
are presented for prescribed synthetic estrogen 
alone (i.e., EE2), prescribed endogenous estro­
gens (i.e., E1, E2, and E3 prescribed for thera­
peutic use), total prescribed estrogens (i.e., E1, 
E2, E3, and EE2 prescribed for therapeutic use), 
naturally occurring endogenous estrogens (i.e., 
naturally occurring animal­derived E1, E2, and 
E3), and total estrogens (E1, E2, E3, and EE2 
from all sources). For dietary and ADI com­
parisons that required combining exposure to 
individual estrogens, total estrogen exposure was 
expressed as estradiol equivalents (E2­eq), which 
were estimated based on alpha receptor binding 
for E1, E2, and E3 (assumed to have relative 
biological activity of 0.1, 1.0, and 0.038, respec­
tively). To avoid potentially under  estimating the 
estrogenic activity of synthetic estrogen, EE2 
was assumed to have 10 times the activity of E2 
(i.e., a relative potency of 10). More detailed dis­
cussion of the relative biological activity adjust­
ments is presented in Supplemental Material 
(doi:10.1289/ehp.0900654.S1).
Dietary benchmarks. Estrogens have 
specific direct and indirect effects that may 
be functions of age as well as sex (Aksglaede 
et al. 2006; Andersson and Skakkebaek 1999; 
Dey et al. 2000). Some potentially sensitive 
subpopulations include prepubescent males 
who have low natural serum estrogen levels 
and an expected low metabolic clearance rate 
(Andersson and Skakkebaek 1999; Klein et al. 
1996), post  menopausal women with naturally 
low estrogen levels, and people with specific 
dietary preferences, such as vegetarians, that 
increase their exposure to phyto  estrogens. We 
examined the differences in total intake of 
estrogens among several different age groups, 
between males and females, and among 
dietary preferences. Women taking prescribed 
estrogens for therapeutic use had the largest 
total daily exposure to estrogens, followed by 
infants fed soy­based formula, then by infants 
on breast milk or milk­based formula, and last 
by children and adults (data not shown).
Given the concern about exposure of pre­
pubescent males (an assumed sensitive sub­
population) to estrogens in drinking water, 
this analysis used estrogen exposure from 
milk consumption of young children as one 
set of dietary benchmarks. The second set of 
dietary benchmarks is the daily exposure of 
an adult female eating an omnivorous diet. 
This is likely to be representative of the daily 
estrogen exposure for the majority of adults in 
the United States.
We estimated dietary exposure to endog­
enous estrogens by combining the reported 
concentrations of estrogens in foodstuffs with 
the average consumption rate of the foodstuff 
[see Supplemental Material, Tables SM­1 
through SM­3 (doi:10.1289/ehp.0900654.
S1)]. Endogenous estrogen intake is likely 
biased low because concentration data for 
one or more estrogens in a particular food 
may be absent and data for other foodstuffs 
expected to contain estrogens have not been 
published. Additionally, this analysis does not 
include the contribution of phyto  estrogens 
to the background estrogenic activity pres­
ent in a typical U.S. diet. Given that adult 
pre  menopausal women are reported to have 
a total isoflavone intake of 1.78 mg/day 
(Horn­Ross et al. 2002) and 2.17 mg/day 
(Huang et al. 2000) and a total lignan intake 
of 0.108 mg/day (Horn­Ross et al. 2002), 
0.525 mg/day (McCann et al. 2003), and 
0.645 mg/day (deKleijn et al. 2002), omis­
sion of phyto  estrogens understates back­
ground dietary estrogen exposure. Although 
biologically active (Masutomi et al. 2004; 
Montani et al. 2008; Rimoldi et al. 2007), Caldwell et al.
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phyto  estrogens were excluded because data 
on their concentrations in many foods are not 
available and their estrogenic potency relative 
to the animal­derived endogenous estrogens 
remains difficult to quantify.
Toxicity-based benchmarks. In addition 
to comparing estrogen exposure via drink­
ing water with background dietary exposure, 
this analysis compares exposure to estrogens 
in drinking water with four independently 
derived ADIs (or sets of ADIs) available in the 
literature.
The WHO (2000) derived an ADI of 
0.05 µg E2/kg body weight (BW)/day based 
on a no observed effect level (NOEL) of 
0.3 mg E2/person/day associated with changes 
in several hormone­dependent parameters. The 
WHO divided the NOEL by an uncertainty 
factor (UF) of 10 to account for “normal vari­
ation” among individuals and a second UF 
of 10 to account for “sensitive populations.” 
In the United States, the assumed adult body 
weight is 60 kg, so the adjusted WHO whole­
body ADI is 3 µg E2/person/day.
The TTC is an acceptable daily exposure 
presented by Kroes et al. (2004) based on a 
review of toxicity data from a variety of chemi­
cals. In the present study, we conservatively 
assumed that estrogens are structurally active 
compounds and evaluated them using the 
TTC of 0.15 µg/person/day derived by Kroes 
et al. (2004) for compounds with a structural 
alert. Such compounds were assigned the low­
est TTC. Had a higher (i.e., less conservative) 
TTC been used, the MOS estimated in this 
analysis would have been higher.
Because EE2 is produced in a manufac­
turing environment, its makers developed 
occupational exposure limits for the protec­
tion of workers using all available toxicologic 
and pharmacologic data to protect against 
potential hazards, primarily from dust inhala­
tion. The myriad biologic responses to estrogen 
exposure argue for use of such an integrated 
assessment of effect in risk assessment. The 
occupational exposure limit is established to 
protect humans against all biologically signif­
icant effects and is based on in vivo studies 
and human experience. The EE2 occupational 
exposure limit of 0.01 µg/m3 used in our 
analysis is the most recent and lowest of five 
occupational exposure limits developed by dif­
ferent manufacturers (Johnson & Johnson, 
unpublished data). It was converted to an 
allowable dose of 0.07 µg EE2/person/day 
by adjusting from an allowable air concentra­
tion to an ADI by multiplying by an assumed 
inhalation rate of 10 m3/person/day and 
multiplying by 5/7 to account for the differ­
ence in number of days a worker is exposed 
per week versus a member of the general   
public. An additional 10­fold reduction to 
account for sensitive populations, in this case 
potential effects on the developing infant, 
results in an ADI of 0.007 µg EE2/person/day. 
Similarly, ADIs of 0.07, 0.02, and 0.07 µg/
person/day for E1, E2, and E3, respectively, 
were derived from their respective occupational 
exposure limits [0.1 µg/m3, 0.029 µg/m3, and 
0.1 µg/m3 (Caldwell DJ, personal communica­
tion; Johnson & Johnson, unpublished data)] 
using the same approach as presented for EE2.
Australia developed water reuse guidelines 
for estrogens (EPHC et al. 2008). Australia 
used the WHO ADI to develop the E2 guide­
line, however; the ADIs for E1, E3, and EE2 
were derived by applying a 10,000­fold safety 
factor to the lowest therapeutic dose, includ­
ing a safety factor of 10 to account for sensi­
tive populations. The resulting ADIs for E1, 
E2, E3, and EE2 are 0.052, 3, 0.084, and 
0.0026 µg/person/day, respectively.
Results
PECs generated by PhATE. PhATE’s ability 
to predict representative surface water con­
centrations has been documented previously 
for a variety of compounds (Anderson et al. 
2004) and more recently for EE2 in a critical 
review comparing surface water PECs with all 
available measured concentrations of EE2 in 
surface water (Hannah et al. 2009). Drinking 
water PECs are slightly lower than surface 
water PECs because drinking water intakes 
are present on < 10% of stream segments, and 
these segments are unlikely to be immediately 
downstream of POTWs. Segments immedi­
ately downstream of POTWs have the highest 
surface water PECs.
The PhATE model is able to gener­
ate PECs associated with various sources of 
estrogens to drinking water. The ability to 
distinguish the relative contribution of dif­
ferent sources points out a unique benefit of 
modeling concentrations because it is not 
possible through measurement, for example, 
to distinguish prescribed E2 from naturally 
occurring E2 in a water sample. Excreted nat­
urally occurring endogenous estrogens have 
the highest drinking water PECs, followed by 
prescribed endogenous estrogens. Prescribed 
synthetic estrogens (i.e., EE2) have the lowest 
PECs (Table 1, Figure 1).
We estimated drinking water exposures 
using the arithmetic mean of drinking water 
PECs assuming 7Q10 low­flow conditions 
(Table 1, Figure 1). The arithmetic mean low­
flow PEC represents the 79th, 78th, and 80th 
percentile of the cumulative drinking water 
system PECs for naturally occurring endog­
enous, prescribed endogenous, and prescribed 
synthetic estrogens, respectively. Use of the 
Table 1. Summary of PECs for three categories of estrogens in U.S. drinking water.
PEC (ng/L)
90th percentile  Average
Category, compound Mean flow Low flow Mean flow Low flow
Endogenous estrogens from diet and naturally produced
E1 0.1 1.1 0.03 0.26
E2 0.02 0.19 0.01 0.05
E3 0.02 0.02 0.01 0.02
Prescribed endogenous estrogens
E1 0.02 0.18 0.01 0.04
E2 0.002 0.02 0.0006 0.005
E3 0.000015 0.000013 0.000006 0.000016
Prescribed synthetic estrogens
EE2 0.003 0.05 0.001 0.01
Figure 1. Cumulative distribution (and arithmetic mean) of PECs generated by PhATE for three differ-
ent categories of estrogens in U.S. drinking water assuming critical low-flow conditions (7Q10). For the 
endogenous estrogens, the combined concentrations of E1, E2, and E3 were not adjusted for differences in 
biological activity.
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arithmetic mean low­flow PEC leads to con­
servative but not extreme estimates of poten­
tial drinking water exposure and is consistent 
with the use of mean, rather than upper bound 
or maximum, concentrations of endogenous 
estrogens in foodstuffs. Most of the time, con­
centrations in drinking water will be lower 
because actual flow will be higher.
Comparison of drinking water to dietary 
exposures. We present two sets of dietary 
comparisons. To address concerns about the 
potential exposures of preadolescent children 
to estrogens predicted to be in drinking water, 
in the first set we compared a young child’s 
exposure to estrogens in drinking water with 
his or her dietary exposure to naturally occur­
ring estrogens in milk (milk consumption is 
encouraged in young children) (Department 
of Health and Human Services 2005). To 
evaluate exposure of the general population, 
we compared an adult’s predicted exposure 
to estrogens via drinking water with an omni­
vore’s exposure to naturally occurring estrogens 
in the overall diet.
The results of the comparison of drinking 
water to dietary estrogen exposures are referred 
to as margins of exposure (MOEs). For the 
young child, we present MOEs for individual 
estrogens as well as all estrogens combined. 
Presenting MOEs on an individual estrogen 
basis allows for the derivation of MOEs with­
out using relative potency adjustments for 
the endogenous estrogens, thus eliminating 
the uncertainty associated with such adjust­
ment factors. A young child’s exposure to 
naturally occurring E1, E2, and E3 through 
typical consumption of milk [assumed to be 
about 0.42 L/day; see Supplemental Material 
(doi:10.1289/ehp.0900654.S1)] is approxi­
mately 730, 5,000, and 480,000 times, 
respectively, greater than his or her exposure 
to trace concentrations of those estrogens pre­
dicted to be in drinking water as a result of 
human therapeutic use (Figure 2). The MOEs 
for naturally occurring endogenous estrogens 
in drinking water (ranging from approxi­
mately 100 to 600; Figure 2) are smaller than 
the MOEs for prescribed estrogens, indicating 
that natural sources of E1, E2, and E3 con­
tribute more to drinking water exposures than 
do prescribed sources.
Because EE2 does not occur naturally in 
milk, we compared a child’s predicted expo­
sure to EE2 via drinking water (expressed as 
E2­eq) with the E2­eq concentration in milk. 
The EE2 drinking water MOE is about 250 
(i.e., a child’s exposure to EE2 in drinking 
water is about 250­fold smaller than his or her 
E2­eq exposure from drinking milk; Figure 2). 
Even when all sources of estrogens in drink­
ing water are considered, the E2­eq exposure 
from drinking water for a young child is about 
150 times lower than the exposure from milk 
alone (Table 2).
Comparison of an adult’s potential expo­
sure to estrogens via drinking water with over­
all dietary intake of E1, E2, and E3 reveals that 
the MOEs for predicted drinking water intake 
vary from 82 to 1,700 depending on estro­
gen category (Table 2). Prescribed endoge­
nous estrogens have the largest MOE (1,700), 
followed by naturally occurring endogenous 
estrogens (MOE = 220), prescribed synthetic 
estrogens (MOE = 140), total prescribed 
(MOE = 130), and finally, total estrogens 
(MOE = 82; Table 2).
Comparison of drinking water exposures to 
toxicity-based benchmarks. The results of the 
comparisons of drinking water estrogen intake 
to toxicity­based benchmarks are referred to 
as margins of safety (MOSs), which provide 
an estimate of how many times smaller the 
predicted drinking water intake is than the 
toxicity­based benchmark. When an adult’s 
potential prescribed estrogen exposures 
(expressed as E2­eq) are compared with the 
WHO ADI of 3 µg E2/person/day, the MOSs 
are about 18,600, 228,000, and 17,000 for 
synthetic prescribed, prescribed endogenous, 
and total prescribed estrogens, respectively 
(Figure 3). Similarly, when the potential expo­
sures are compared with the TTC of 0.15 µg/
person/day, MOSs are about 930, 11,400, 
and 860 for synthetic, prescribed endogenous, 
and total prescribed estrogens, respectively 
(Figure 3). The MOS for naturally occurring 
estrogens (referred to as “Total endogenous” 
in Figure 3) is about two times higher than 
that for prescribed synthetic estrogens, and 
the MOS for total estrogen exposure from 
drinking water is about 1.5 times smaller 
than that for the total prescribed estrogen 
MOS (Figure 3). When the potential drink­
ing water exposures to prescribed E1, E2, E3, 
and EE2 are compared with their respective 
occupational exposure limit–derived ADIs, 
the MOSs for adults are equal to about 1,150, 
3,070, 3,200,000, and 441, respectively, and 
the combined MOS is 289 (Figure 3). The 
adult MOSs for prescribed E1, E2, E3, and 
EE2 in drinking water based on the Australian 
guidelines (EPHC et al. 2008) are about 840, 
440,000, 3,700,000, and 160, respectively, 
and the combined MOS is 135 (Figure 3). 
MOSs for young children are approximately 
two times smaller than those for adults because 
young children are assumed to consume about 
two times more water on a per kilogram basis 
than do adults. The lowest MOSs for children 
result from comparing total prescribed estro­
gens (MOS = 55) and total of all estrogens 
combined (prescribed and naturally occur­
ring, MOS = 28) in drinking water with ADIs 
derived from the Australian guidelines.
The WHO ADI is derived by applying 
commonly used UFs to therapeutic doses given 
to post  menopausal women. Although one of 
these UFs was intended to account for sensi­
tive individuals, is it possible that a UF of 10 
may not fully account for differences in sen­
sitivity between postmenopausal women and 
either men/boys or children? Recent multi­
generational studies have examined the effects 
of exposure to either E2 or EE2 during gesta­
tion and early life stages on the reproductive 
system of young male rodents (Howdeshell 
et al. 2008; Latendresse et al. 2009; Tyl et al. 
2008). Howdeshell et al. (2008) reported a 
NOEL of 1.5 µg EE2/kg BW/day, equal to 
Figure 2. MOEs (equal to the predicted estrogen 
intake from milk divided by the predicted estrogen 
intake from drinking water) for a young child. For 
E1, E2, and E3, MOEs are shown for exposure to 
prescribed estrogens predicted to be in drinking 
water and for naturally occurring estrogens pre-
dicted to be in drinking water. A single MOE is 
shown for EE2 because the only source of EE2 in 
drinking water is assumed to be therapeutic use 
(i.e., prescribed). MOEs for E1, E2, and E3 are based 
on the mass-based concentration of each estrogen 
in drinking water and milk. The EE2 MOE is based 
on the E2-eq concentration of EE2 in drinking water 
and of E1, E2, and E3 combined in milk. 
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Table 2. MOEs for a child and an adult.
Child Adult
Estrogen 
Drinking water intakea 
(mg/person-day) MOEb
Drinking water intakea 
(mg/person-day) MOEc
Prescribed endogenous estrogens 8.2 × 10–9  3,200 1.3 × 10–8  1,700
Naturally occurring endogenous estrogens 6.6 × 10–8  400 1.1 × 10–7  220
Prescribed synthetic estrogens 1.0 × 10–7  260 1.6 × 10–7  140
Total prescribed estrogens 1.1 × 10–7  240 1.7 × 10–7  130
Total estrogens from all sources 1.7 × 10–7  150 2.8 × 10–7  82
aExpressed as E2-eq. bCompared with a child’s milk intake of 2.6 × 10–5 mg/person-day (expressed as E2-eq). cCompared 
with an adult dietary intake of 2.3 × 10–5 mg/person-day (expressed as E2-eq).Caldwell et al.
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90 µg EE2/person/day, and Tyl et al. (2008) 
reported a NOEL of 1 µg E2/kg BW/day, 
equal to 60 µg E2/person/day, assuming a 
body weight of 60 kg. Latendresse et al. (2009) 
summarized results from National Toxicology 
Program (NTP) studies of chronic and multi­
generational reproductive effects of EE2. 
These authors observed an overall no observed 
adverse effect level for reproductive effects of 
0.7 µg/kg/day in the five­generation reproduc­
tion study. Both the chronic and reproduc­
tive studies summarized by Latendresse et. al. 
(2009) reported male mammary gland hyper­
plasia. The increase seen in the low­dose group 
(0.1 µg/kg/day) of the reproduction study was 
marginal in the F1 generation, and there was no 
difference from controls in the F0, F2, F3, F4, 
or F5 generations. There was no clear evidence 
that mammary gland hyperplasia progressed to 
neoplasia, nor was there amplification of mam­
mary hyperplasia in the continuously exposed 
F2 progeny (i.e., offspring of the F1 genera­
tion that also were continuously exposed). This 
indicates there was no carryover of effect from 
generation to generation (Latendresse et al. 
2009). Thus, an overall NOEL based on an 
endocrine­sensitive end point is 0.1 µg/kg/day 
for males continuously exposed from the time 
the F0 generation was 6 weeks of age through 
weaning of the F3 generation.
If one were to apply UFs of 10 each for 
inter  species and intraspecies extrapolation and 
sensitive populations (total UF of 1,000), the 
resulting ADIs would be 0.09 µg EE2/person/ 
day and 0.06 µg E2/person/day, respec­
tively, for Tyl et al. (2008) and Howdeshell 
et al. (2008). We conclude that the study by 
Latendresse et al. (2009) does not require 
the additional UF for sensitive populations 
because it was conducted on that population, 
and the ADI would be 0.06 µg EE2/person/
day. These ADIs fall within the range of the 
other toxicity benchmarks used in the present 
study. These recent studies suggest that large 
MOSs (> 25) would also exist when potential 
exposures to prescribed estrogens in drinking 
water are compared with ADIs derived spe­
cifically to be protective of reproductive effects 
in young males. Based on Latendresse et al. 
(2009) reporting an NOEL for an endocrine­
sensitive end point in a potentially sensitive 
population exposed continuously over mul­
tiple generations, application of an additional 
UF of 10 is protective. Thus, the use of a single 
UF of 10 to account for sensitive populations 
is a conservative practice.
Discussion
The large MOEs that result when predicted 
drinking water exposures of adults and young 
children are compared with dietary exposures 
is an important finding. Although we do not 
know whether dietary exposures to estrogens 
are or are not associated with effects (adverse 
or beneficial), we do know they represent a 
consistent daily exposure for U.S. residents. 
Documenting that the potential exposure to 
total estrogens (prescribed and naturally occur­
ring) in drinking water is at least 82 times 
lower than our natural background dietary 
exposure suggests that exposures to estrogens 
(prescribed or naturally occurring) in drinking 
water are inconsequential and should have no 
effect. Indeed, it is likely that naturally occur­
ring day­to­day variation in dietary intake 
(e.g., having a glass of milk or some cheese one 
day and not the next) will lead to much larger 
variations in estrogen exposure than is associ­
ated with drinking water intake of prescribed 
estrogens or naturally occurring estrogens.
Similarly, the large MOSs that result when 
predicted drinking water exposures are com­
pared with several toxicity­based benchmarks 
are also an important finding and indicate that 
predicted drinking water exposures to estrogens 
are not expected to be associated with adverse 
effects in the U.S. population. Although there 
is no consistent approach for applying safety 
factors for infants and children or other sen­
sitive subgroups, the combined safety factor 
applied to the toxicity­based benchmarks for 
intra  species variability and protection of sen­
sitive subgroups adequately addresses issues 
associated with potential exposure of the devel­
oping fetus, infants, and children. Application 
of an additional safety factor of 10, as done 
in this analysis, is a conservative approach, as 
borne out by Latendresse et al. (2009) in the 
summary of the NTP studies. It is also con­
sistent with the Food Quality Protection Act 
of 1996, which applies a default safety factor 
of 10 for sensitive subpopulations when deal­
ing with pesticides in food products. Given 
that some of the ADIs we used in the present 
analysis are derived to be protective of sensitive 
sub  populations, such as pre  pubescent boys, the 
conclusion of an absence of an effect should 
extend to all segments of the U.S. population.
Even though the MOEs and MOSs 
resulting from all of the comparisons of estro­
gens in drinking water are consistently large, 
the question remains whether the uncertainty 
associated with the present analysis could lead 
to a substantially lower MOE or MOS. An 
under  estimate of the MOE and MOS asso­
ciated with prescribed and naturally occur­
ring endogenous estrogens seems unlikely 
for several reasons. Perhaps most impor­
tant is that we did not account for potential 
removal of estrogens by drinking water treat­
ment plants. Few studies have examined such 
removal. However, in a recent study Benotti 
et al. (2009) reported drinking water treat­
ment system removal rates of at least 80% 
and as much as 99% for E1, E2, and EE2 
(E3 removal was not meas  ured). In the pres­
ent study, incorporating these removal data 
would have reduced predicted drinking water 
exposures (and, therefore, increased MOEs 
and MOSs) by at least 5­fold and likely more. 
Figure 3. MOSs for adult exposure to estrogens via drinking water for the WHO ADI, the TTC, four ADIs 
derived from OELs, and the four ADIs used to derive the Australian guidelines (EPHC et al. 2008). For the 
WHO ADI and the TTC, five MOSs are presented corresponding to five categorizations of estrogens pre-
dicted to be in drinking water. MOSs for the WHO ADI and TTC are based on estrogen intakes expressed 
as E2-eq (i.e., are activity adjusted), as are the MOSs for total prescribed and total all sources compari-
sons to OELs and Australian guidelines, whereas MOSs for the individual estrogens for OEL and Australian 
guideline comparisons are based on estrogen intakes expressed on a mass basis (i.e., are not activity 
adjusted because the estrogen-specific ADIs embody differences in activity).
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MOEs derived from the dietary comparisons 
would also have been larger if concentrations 
of naturally occurring endogenous estrogens 
were available for all the foods in our diet and 
if the contribution of phyto  estrogens to the 
estrogen content in food had been included.
MOEs and MOSs may be over  estimated 
for some drinking water systems. The arith­
metic mean is equal to approximately the 80th 
percentile of the distribution of drinking water 
PECs (Figure 1, Table 1). That means approxi­
mately 20% of drinking water systems included 
in PhATE have critical low­flow PECs greater 
than those used in this analysis. The maximum 
critical low­flow drinking water PEC is about 
10 times greater than the arithmetic mean PEC 
(Figure 1). The MOEs and MOSs correspond­
ing to the maximum PEC would be about 
10 times smaller than those associated with 
the mean PEC used in this analysis. However, 
even if we use the maximum PEC generated 
by PhATE, prescribed estrogens predicted to 
be in drinking water still represent a fraction 
of background dietary estrogen exposure and 
remain below ADIs; thus, adverse effects are 
not expected.
MOEs and MOSs for estrogen exposure 
from all sources in drinking water may also 
be reduced in situations where drinking water 
system source water contains endogenous 
hormones from upstream animal husbandry 
opera  tions or from pharmaceutical manufac­
turing. Such operations are not included in 
PhATE because information on the location 
and magnitude of such sources is not readily 
available for most watersheds. The effect on 
most drinking water PECs of not including 
animal husbandry sources is expected to be 
small, given that most drinking water systems 
are likely to be near populated areas of water­
sheds and such areas are less likely to have ani­
mal husbandry operations than more remote 
areas of the watersheds. The effect on most 
drinking water PECs of not including pharma­
ceutical manufacturing sources is also expected 
to be small given that most pharmaceutical 
manufacturing sources provide onsite waste­
water treatment and/or discharge to POTWs.
MOEs and MOSs for total estrogenic 
activity in drinking water may also be lower 
than shown by this analysis because com­
pounds other than the endogenous and pre­
scribed hormones that are the focus of this 
study may be present in POTW effluents. A 
comprehensive assessment of the potential 
effect of these other compounds is beyond 
the scope of this analysis. However, several 
studies investigating the overall estrogenic 
activity of POTW effluents report that most 
estrogenic activity is attributable to E1, E2, 
E3, and EE2 (Aerni et al. 2004; Desbrow 
et al. 1998; Houtman et al. 2007; Salste et al. 
2007). These results suggest that even if the 
estrogenic potential of the other compounds 
present in POTW effluents were included, the 
MOEs and MOSs estimated by this analysis 
would decrease by no more than about 2­fold.
One potential group of people who may 
have lower surface­water–related MOEs and 
MOSs than estimated here are anglers who 
consume self­caught fresh  water fish. A bio­
concentration factor of 635 has been reported 
for EE2 (Länge et al. 2001). Assuming that 
rate of bioaccumulation is representative of 
EE2 bioaccumulation in natural waters, an 
angler consuming 6.5 g of fish from the same 
surface water that serves as the source of his 
or her drinking water supply is exposed to 
as much EE2 through the consumption of 
fish as is present in 4.1 L of water, or about 
2.25 times more daily exposure than he or 
she gets from drinking water. Although this 
does not alter the conclusions of this analysis 
because the MOEs and MOSs remain very 
large, it does indicate that, for some people, 
potential exposure to estrogens via consump­
tion of fish may result in greater exposure 
than from consumption of drinking water.
Conclusion
The large MOEs and MOSs determined in the 
present study appear robust and are more likely 
to understate than overstate actual MOEs and 
MOSs. The dietary comparison indicates that 
potential exposures to trace levels of total estro­
gens (whether from a prescribed or naturally 
occurring source) predicted to be in drinking 
water in the United States are at least 82 times 
lower than exposures from background con­
centrations of naturally occurring estrogens 
in the diet. Drinking water exposures are also 
at least 28 times less than ADIs developed to 
be protective of sensitive populations. Taken 
together, the finding of consistently large 
MOEs and MOSs across all lines of evidence 
strongly suggests that concentrations of estro­
gens (including prescribed estrogens) predicted 
by PhATE to potentially be in drinking water 
are not causing adverse effects in U.S. residents, 
including sensitive subpopulations.
cO r r e c t i O n
In the original manuscript published 
online, some exposure estimates and mar­
gins of safety were incorrect. They have 
been corrected here.
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